摘要
１１ 例急性白血病及中－ 高恶性度非何杰金氏淋巴瘤患者，采用自体／异基因骨髓移植和外周血造血祖细胞保护的大剂量化疗。骨髓或外周血造血祖细胞回输后，开始使用Ｇ－ ＣＳＦ ２．５－ ５ μｇ／ｋｇ，１／日。Ｇ－ＣＳＦ使用天数分别为：外周血造血祖细胞保护组１１±２ ｄ；自体骨髓移植组１８±２ ｄ；异基因骨髓移植组２０±２ ｄ。骨髓涂片显示：骨髓增生活跃。外周血象恢复时间缩短，骨髓及外周血ＣＦＵ－ＧＭ ，ＢＦＵ－Ｅ， ＣＦＵ －ｍ ｉｘ 培养和ＣＤ３４＋ ＣＤ３８＋ 、ＣＤ３４＋ ＣＤ３８－ 细胞检测表明造血祖细胞恢复良好。Ｇ－ＣＳＦ能促进骨髓造血重建，缩短骨髓空虚期。
Eleven patients with acute leukemia or intermediate- and high grade non Hodgkin's lymphoma received autologous/allogeneic bone marrow transplantation(BMT) or high dose chemotherapy supported by peripheral blood progenitor cells(PBPC). G CSF was begun to use at the dose of 2.5～5 μg/kg/day after the bone marrow or the peripheral blood progenitor cells were reinfused. The time for G-CSF usage was 11±2 days in the patients with PBPC support, 18±2 days in autologous BMT and 20±2 days in allogeneic BMT. Bone marrow smear showed hypercellularity especially in granulocyte. Recovery time for peripheral blood routine was short. The assays of CFU GM, BFU E, CFU mix, CD 34 +CD 38 + cells and CD 34 +CD 38 - cells in bone marrow and in peripheral blood confirmed that the hematopoietic cells recovered well. It suggests that G CSF can promote hematopoietic reconstruction, short the empty time of bone marrow and reduce the chance of sever infection.
出处
《空军总医院学报》
1997年第2期73-76,共4页
Journal of General Hospital of Air Force,PLA
关键词
粒细胞集落刺激因子
骨髓移植
外周血
骨髓造血重建
造血干细胞
Bone marrow transplantation Peripheral blood stem cells Granulocyte growth factors Progenitor assays
